There were 2,262 press releases posted in the last 24 hours and 438,128 in the last 365 days.

North American Drug Delivery Technologies Market by Route of Administration, End User - Global Forecast to 2021

Dublin, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "North American Drug Delivery Technologies Market by Route of Administration, End User - Global Forecast to 2021" report to their offering.

The North American drug delivery technologies market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5% during the forecast period.

Factors such as rising prevalence of chronic diseases, growth in the biologics market, funding initiatives for drug delivery research, and technological advancements are driving the growth of the North American drug delivery technologies market. However, risk of needlestick injuries and side effects related to drugs are expected to restrain the growth of this market in the coming years.

Based on the route of administration, the North American drug delivery technologies market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery market is expected to grow at the highest CAGR during the forecast period. The high growth in this segment is attributed to the advantages of topical drugs, such as convenience and ease of use, right dosage to the right place, painless application, noninvasive nature, superior spreadability, and enhanced patient compliance.

On the basis of type, the oral drug delivery technologies market is segmented into solid, liquid, and semi-solid drug delivery. Solid oral drug delivery is segmented into tablets, capsules, pills, and powders. In 2016, tablets are estimated to account for the largest share of the solid oral drug delivery market. High patient compliance and acceptability are the major factors driving the growth of this market segment.

The injectable drug delivery market is segmented into two broad categories, namely, devices and formulations. Devices are further subsegmented into conventional and self-injectors, while formulations are further categorized into conventional, novel, and long-acting. In 2016, novel drug delivery formulations are expected to account for the largest share of the formulations market. Enhanced efficacy, increased patient compliance by decreasing dose frequency, and targeted drug delivery (which reduces side effects) are some of the key factors driving the growth of this market segment.

Topical drug delivery is segmented into solid, liquid, semi-solid, and transdermal drug delivery. Transdermal drug delivery is expected to register the highest CAGR during the forecast period. The noninvasive nature of this drug delivery system, feasibility of self-administration, and improved patient compliance are the major factors driving the growth of the transdermal drug delivery market.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Regulatory Environment

7 North American Drug Delivery Technologies Market, By Route Of Administration

8 North American Drug Delivery Technologies Market, By End User

9 North American Drug Delivery Technologies Market, By Country

10 Competitive Landscape

11 Company Profiles

  • 3M Company
  • Antares Pharma, Inc.
  • Bayer Ag
  • Becton, Dickinson And Company
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis Ag
  • Pfizer, Inc.
  • Sanofi

For more information about this report visit http://www.researchandmarkets.com/research/kqqvzs/north_american

Related Topics: Drug Delivery


CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.